NHS makes 'final' offer to Vertex

David Ramsden, chief executive of the U.K.-based Cystic Fibrosis Trust, tweeted out a letter he received from NHS England that detailed what the agency said was its "final proposal" to Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) regarding reimbursement of its cystic fibrosis drugs.

NHS England confirmed the authenticity of the letter to BioCentury.

According to the July 16 letter, the proposed five-year deal would guarantee immediate and expanded access for patients to Kalydeco ivacaftor

Read the full 709 word article

User Sign In